8 Emerging Bispecific Antibodies Revolutionizing Non-Small Cell Lung Cancer (NSCLC) Treatment

July 04, 2025

The landscape of non-small cell lung cancer (NSCLC) therapy is undergoing a significant shift with the advent of bispecific antibodies. These innovative agents simultaneously target multiple immune checkpoints and tumor-promoting pathways, ushering in a new era of combination immunotherapy. Among the most groundbreaking are bispecific PD-1/vascular endothelial growth factor (VEGF) antibodies, engineered to tackle immune resistance and inhibit angiogenesis.

Explore ongoing PD-1/VEGF bispecific trials and their impact on lung cancer therapy today: https://www.delveinsight.com/blog/bispecific-antibodies-for-nsclc?utm_source=blog&utm_medium=promotion&utm_campaign=akpr

One of the most extensively investigated candidates is ivonescimab (AK112), currently being evaluated in Phase I/II clinical trials (NCT05499390 – recruiting). While the trial NCT05184712 for ivonescimab (AK112) remains a central focus, new bispecific PD-1/vascular endothelial growth factor antibody clinical trials are rapidly emerging, introducing alternative therapies beyond AK112. The clinical trial landscape for PD-1/vascular endothelial growth factor bispecific monoclonal antibodies outside of AK112 is expanding swiftly, with multiple candidates showing encouraging potential.

A notable entrant is PM8001, a bispecific programmed death-ligand 1 (PD-L1)/vascular endothelial growth factor antibody co-developed by Bio-Thera and BeiGene. The ongoing PM8001 PD-L1/vascular endothelial growth factor bispecific clinical trial (including the PM8001 trial registered under NCT) is progressing through early-stage development, representing a novel dual-targeting strategy. These bispecific PD-1/vascular endothelial growth factor monoclonal antibody clinical trials — beyond AK112 — are redefining the therapeutic potential of immunotherapy in lung cancer.

Another promising molecule is GEN1046 from Genmab, a bispecific antibody targeting PD-L1 and 4-1BB. The GEN1046 Genmab development program signifies a new class of bispecific formats, garnering attention alongside established epidermal growth factor receptor (EGFR)/MET bispecific antibodies such as amivantamab, which has already received United States Food and Drug Administration (FDA) approval for specific NSCLC populations.

Several trials currently recruiting participants, including NCT04900363, NCT05499390 (AK112), and other PD-1/vascular endothelial growth factor bispecific monoclonal antibody clinical trials active in 2024, are advancing the pipeline forward. Key studies like the “bispecific monoclonal antibody PD-1/vascular endothelial growth factor clinical trial active recruiting October 2024” and the HB0025 PD-1/vascular endothelial growth factor bispecific trial (NCT identifier) are being watched closely for updates.

Discover how bispecific antibodies are changing NSCLC treatment—learn more in this clinical trial update: https://www.delveinsight.com/blog/bispecific-antibodies-for-nsclc?utm_source=blog&utm_medium=promotion&utm_campaign=akpr

As the ongoing PD-1/vascular endothelial growth factor bispecific antibody clinical trial landscape continues to evolve, bispecific antibody therapies in lung cancer hold great promise for enhancing patient outcomes. The bispecific PD-1/vascular endothelial growth factor monoclonal antibody field is on track for significant progress by 2025, with the potential to redefine the treatment paradigm for NSCLC.